8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 6, 2026·SEC
Cyclerion Therapeutics, Inc.(CYCN)Earnings, Financials & Key Ratios
CYCN•NASDAQ
$3.24
$14M mkt cap·Price updated May 6, 2026
AboutCyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$2M+3.7%
- EBITDA-$5M-37.1%
- Net Income-$4M-15.4%
- EPS (Diluted)-1.09+9.9%
- Gross Margin100%
- EBITDA Margin-239.78%-32.2%
- Operating Margin-239.78%-32.2%
- Net Margin-170.11%-11.3%
- ROE-39.34%-29.6%
- ROIC-65.07%-11.6%
CYCN Key Insights
Cyclerion Therapeutics, Inc. (CYCN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 46.1%
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 28.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CYCN Price & Volume
Cyclerion Therapeutics, Inc. (CYCN) stock price & volume — 10-year historical chart
Loading chart...
CYCN Growth Metrics
Cyclerion Therapeutics, Inc. (CYCN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-2.01%
3 Years91.14%
TTM3.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0.81%
Return on Capital
10 Years-81.22%
5 Years-69.81%
3 Years-70.21%
Last Year-55.46%
CYCN Peer Comparison
Cyclerion Therapeutics, Inc. (CYCN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KALA | 855.53K | 0.12 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 |
Compare CYCN vs Peers
Cyclerion Therapeutics, Inc. (CYCN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CYCN Income Statement
Cyclerion Therapeutics, Inc. (CYCN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 4.51M | 2.3M | 3.32M | 297K | 0 | 2M | 2.07M |
| Revenue Growth % | - | - | - | -49.06% | 44.6% | -91.05% | -100% | - | 3.7% |
| Cost of Goods Sold | 1.75M | 1.53M | 95.14M | 56.41M | 0 | 5.58M | 0 | 0 | 0 |
| COGS % of Revenue | - | - | 2110.94% | 2457.06% | - | 1878.45% | - | - | - |
| Gross Profit | -1.75M▲ 0% | -1.53M▲ 12.4% | -90.63M▼ 5831.5% | -54.12M▲ 40.3% | 3.32M▲ 106.1% | -5.28M▼ 259.1% | 0▲ 100.0% | 2M▲ 0% | 2.07M▲ 3.7% |
| Gross Margin % | - | - | -2010.94% | -2357.06% | 100% | -1778.45% | - | 100% | 100% |
| Gross Profit Growth % | - | 12.44% | -5831.48% | 40.29% | 106.13% | -259.1% | 100% | - | 3.7% |
| Operating Expenses | 93.92M | 115.25M | 34.4M | 27.15M | 58.52M | 13.26M | 12.95M | 5.63M | 7.05M |
| OpEx % of Revenue | - | - | 763.35% | 1182.36% | 1762.5% | 4463.97% | - | 281.4% | 339.78% |
| Selling, General & Admin | 15.12M | 27.54M | 34.4M | 28.82M | 20.62M | 13.26M | 8.33M | 5.34M | 6.09M |
| SG&A % of Revenue | - | - | 763.35% | 1255.05% | 621.08% | 4463.97% | - | 267.1% | 293.54% |
| Research & Development | 78.8M | 87.72M | 95.14M | 56.41M | 37.64M | 5.98M | 1.51M | 286K | 959K |
| R&D % of Revenue | - | - | 2110.94% | 2457.06% | 1133.61% | 2013.13% | - | 14.3% | 46.24% |
| Other Operating Expenses | 0 | 0 | -95.14M | -58.08M | 259K | -5.98M | 3.1M | 0 | 0 |
| Operating Income | -93.92M▲ 0% | -115.25M▼ 22.7% | -125.04M▼ 8.5% | -81.27M▲ 35.0% | -55.2M▲ 32.1% | -18.54M▲ 66.4% | -12.95M▲ 30.1% | -3.63M▲ 72.0% | -4.97M▼ 37.1% |
| Operating Margin % | - | - | -2774.28% | -3539.42% | -1662.5% | -6242.42% | - | -181.4% | -239.78% |
| Operating Income Growth % | - | -22.71% | -8.49% | 35.01% | 32.08% | 66.41% | 30.15% | 71.99% | -37.07% |
| EBITDA | -92.18M | -113.72M | -122.34M | -78.97M | -54.72M | -18.48M | -12.89M | -3.63M | -4.97M |
| EBITDA Margin % | - | - | -2714.38% | -3439.37% | -1648.28% | -6220.54% | - | -181.4% | -239.78% |
| EBITDA Growth % | - | -23.38% | -7.57% | 35.45% | 30.7% | 66.24% | 30.25% | 71.85% | -37.07% |
| D&A (Non-Cash Add-back) | 1.75M | 1.53M | 2.7M | 2.3M | 472K | 65K | 65K | 0 | 0 |
| EBIT | -93.92M | -115.25M | -125.04M | -82.93M | -54.31M | -18.54M | -9.65M | -3.63M | -4.97M |
| Net Interest Income | 0 | 0 | 2.03M | 588K | -16K | 294K | 358K | 208K | 128K |
| Interest Income | 0 | 0 | 2.03M | 588K | 0 | 294K | 358K | 208K | 128K |
| Interest Expense | 0 | 0 | 0 | 0 | 16K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | 0 | 2.03M | 3.46M | 3.55M | 294K | 358K | 571K | 1.45M |
| Pretax Income | -93.92M▲ 0% | -115.25M▼ 22.7% | -123.01M▼ 6.7% | -77.8M▲ 36.8% | -51.65M▲ 33.6% | -18.25M▲ 64.7% | -12.59M▲ 31.0% | -3.06M▲ 75.7% | -3.53M▼ 15.4% |
| Pretax Margin % | - | - | -2729.27% | -3388.59% | -1555.63% | -6143.43% | - | -152.85% | -170.11% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -93.92M▲ 0% | -115.25M▼ 22.7% | -123.01M▼ 6.7% | -77.8M▲ 36.8% | -51.65M▲ 33.6% | -44.08M▲ 14.7% | -5.26M▲ 88.1% | -3.06M▲ 41.9% | -3.53M▼ 15.4% |
| Net Margin % | - | - | -2729.27% | -3388.59% | -1555.63% | -14841.08% | - | -152.85% | -170.11% |
| Net Income Growth % | - | -22.71% | -6.73% | 36.75% | 33.62% | 14.66% | 88.06% | 41.92% | -15.41% |
| Net Income (Continuing) | -93.92M | -115.25M | -123.01M | -77.8M | -51.65M | -18.25M | -12.59M | -3.06M | -3.53M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -25.83M | 7.33M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -68.80▲ 0% | -84.42▼ 22.7% | -88.37▼ 4.7% | -47.80▲ 45.9% | -26.40▲ 44.8% | -20.15▲ 23.7% | -8.99▲ 55.4% | -1.21▲ 86.5% | -1.09▲ 9.9% |
| EPS Growth % | - | -22.7% | -4.68% | 45.91% | 44.77% | 23.67% | 55.38% | 86.54% | 9.92% |
| EPS (Basic) | -68.80 | -84.42 | -88.37 | -47.80 | -26.40 | -20.15 | -8.99 | -1.21 | -1.09 |
| Diluted Shares Outstanding | 1.37M | 1.37M | 1.37M | 1.52M | 1.96M | 2.17M | 2.34M | 2.52M | 3.23M |
| Basic Shares Outstanding | 1.37M | 1.37M | 1.37M | 1.52M | 1.96M | 2.17M | 2.34M | 2.52M | 3.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CYCN Balance Sheet
Cyclerion Therapeutics, Inc. (CYCN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.26M | 879K | 101.2M | 58.5M | 55.46M | 14.82M | 8.02M | 4.22M | 4.63M |
| Cash & Short-Term Investments | 0 | 0 | 97.59M | 54.4M | 53.96M | 13.38M | 7.57M | 3.23M | 3.24M |
| Cash Only | 0 | 0 | 97.59M | 54.4M | 53.96M | 13.38M | 7.57M | 3.23M | 3.24M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 1.47M | 127K | 100K | 96K | 0 | 556K | 1M |
| Days Sales Outstanding | - | - | 119.37 | 20.19 | 10.99 | 117.98 | - | 101.47 | 175.99 |
| Inventory | 0 | 0 | 0 | 0 | 928K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 8K | 12K | 162K | 1.56M | 468K | 537K | 11K | 16K | 11K |
| Total Non-Current Assets | 4.21M | 6.52M | 85.28M | 56.88M | 3.87M | 3.26M | 5.35M | 5.35M | 5.35M |
| Property, Plant & Equipment | 4.13M | 6.5M | 79.75M | 50.27M | 1.47M | 1.22M | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | 0.06x | 0.05x | 2.26x | 0.24x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 4.99M | 0 | 0 | 0 | 5.35M | 5.35M | 5.35M |
| Other Non-Current Assets | 80K | 25K | 540K | 6.61M | 2.41M | 2.04M | 0 | 0 | 0 |
| Total Assets | 5.47M▲ 0% | 7.4M▲ 35.3% | 186.48M▲ 2419.6% | 115.38M▼ 38.1% | 59.33M▼ 48.6% | 18.08M▼ 69.5% | 13.37M▼ 26.0% | 9.57M▼ 28.4% | 9.98M▲ 4.3% |
| Asset Turnover | - | - | 0.02x | 0.02x | 0.06x | 0.02x | - | 0.21x | 0.21x |
| Asset Growth % | - | 35.3% | 2419.63% | -38.13% | -48.58% | -69.53% | -26.02% | -28.41% | 4.28% |
| Total Current Liabilities | 14.04M | 17.85M | 18.25M | 16.95M | 11.09M | 7.63M | 2.09M | 725K | 900K |
| Accounts Payable | 1.8M | 2.78M | 3.31M | 1.15M | 1.83M | 2.97M | 1.2M | 390K | 508K |
| Days Payables Outstanding | 376.92 | 664.31 | 12.7 | 7.43 | - | 194.31 | - | - | - |
| Short-Term Debt | 0 | 0 | 3.42M | 3.51M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.62M | 7.27M | 5.05M | 176K | 7.28M | 68K | 102K | 63K | 51K |
| Current Ratio | 0.09x | 0.05x | 5.55x | 3.45x | 5.00x | 1.94x | 3.85x | 5.83x | 5.15x |
| Quick Ratio | 0.09x | 0.05x | 5.55x | 3.45x | 4.92x | 1.94x | 3.85x | 5.83x | 5.15x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 70.5M | 38.93M | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 70.5M | 38.93M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.04M | 17.85M | 88.75M | 55.88M | 11.09M | 7.63M | 2.09M | 725K | 900K |
| Total Debt | 0 | 0 | 73.92M | 45.73M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 0 | 0 | -23.68M | -8.66M | -53.96M | -13.38M | -7.57M | -3.23M | -3.24M |
| Debt / Equity | - | - | 0.76x | 0.77x | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -3394.63x | - | - | - | - |
| Total Equity | -8.57M▲ 0% | -10.45M▼ 21.9% | 97.73M▲ 1035.7% | 59.49M▼ 39.1% | 48.25M▼ 18.9% | 10.45M▼ 78.3% | 11.29M▲ 8.0% | 8.85M▼ 21.6% | 9.09M▲ 2.7% |
| Equity Growth % | - | -21.92% | 1035.65% | -39.12% | -18.9% | -78.34% | 8% | -21.6% | 2.66% |
| Book Value per Share | -6.28 | -7.65 | 71.39 | 39.14 | 24.65 | 4.81 | 4.83 | 3.51 | 2.82 |
| Total Shareholders' Equity | -8.57M | -10.45M | 97.73M | 59.49M | 48.25M | 10.45M | 11.29M | 8.85M | 9.09M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 0 | 0 | -85.63M | -163.43M | -215.08M | -259.15M | -264.42M | -267.49M | -271.02M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -15.87M | -15.49M | -20K | -27K | -23K | -20K | -12K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYCN Cash Flow Statement
Cyclerion Therapeutics, Inc. (CYCN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -81.22M | -97.5M | -102.22M | -72.49M | -36.52M | -40.61M | -21.25M | -4.33M | -3.31M |
| Operating CF Margin % | - | - | -2267.92% | -3157.23% | -1099.91% | -13673.74% | - | -216.65% | -159.79% |
| Operating CF Growth % | - | -20.05% | -4.83% | 29.08% | 49.62% | -11.21% | 47.69% | 79.6% | 23.52% |
| Net Income | -93.92M | -115.25M | -123.01M | -77.8M | -51.65M | -18.25M | -12.59M | -3.06M | -3.53M |
| Depreciation & Amortization | 1.75M | 1.53M | 2.7M | 2.3M | 472K | 65K | 0 | 0 | 0 |
| Stock-Based Compensation | 9.49M | 12.43M | 19.63M | 14.99M | 9.61M | 0 | 0 | 625K | 441K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12.59M | 14.51M | 751K | -4.38M | 3.64M | -19.58M | -4.05M | -363K | 0 |
| Working Capital Changes | 1.47M | 3.79M | -2.29M | -7.59M | 1.41M | -2.85M | -4.6M | -1.54M | -227K |
| Change in Receivables | 0 | 0 | -1.47M | 1.35M | 27K | 4K | 96K | -556K | -444K |
| Change in Inventory | 0 | 0 | -3.18M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 392K | 979K | -250K | -1.1M | 393K | 1.14M | -1.77M | -445K | 118K |
| Cash from Investing | -1.4M | -3.44M | -6.71M | 18K | 1.46M | 0 | 10.4M | 0 | 0 |
| Capital Expenditures | -1.4M | -3.44M | -6.89M | -1.52M | -7K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | 152.83% | 66.38% | 0.21% | - | - | - | - |
| Acquisitions | 0 | 0 | 173K | 0 | 0 | 0 | 10.4M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 173K | 1.54M | 1.46M | 0 | 0 | 0 | 0 |
| Cash from Financing | 82.62M | 100.94M | 211.57M | 28.09M | 30.79M | 29K | 5.02M | 0 | 3.32M |
| Debt Issued (Net) | 0 | 0 | 0 | 3.51M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 175M | 24.25M | 30.5M | 29K | 5.02M | 0 | 1.25M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -130K |
| Other Financing | 82.62M | 100.94M | 36.57M | 331K | 282K | 0 | 0 | 0 | 2.08M |
| Net Change in Cash | 0▲ 0% | 0▲ 0% | 102.62M▲ 0% | -44.39M▼ 143.3% | -4.27M▲ 90.4% | -40.58M▼ 850.1% | -5.81M▲ 85.7% | -4.34M▲ 25.3% | 8K▲ 100.2% |
| Free Cash Flow | -82.62M▲ 0% | -100.94M▼ 22.2% | -109.1M▼ 8.1% | -74.01M▲ 32.2% | -36.52M▲ 50.7% | -40.61M▼ 11.2% | -21.25M▲ 47.7% | -4.33M▲ 79.6% | -3.31M▲ 23.5% |
| FCF Margin % | - | - | -2420.75% | -3223.61% | -1100.12% | -13673.74% | - | -216.65% | -159.79% |
| FCF Growth % | - | -22.17% | -8.09% | 32.16% | 50.65% | -11.19% | 47.69% | 79.6% | 23.52% |
| FCF per Share | -60.52 | -73.94 | -79.70 | -48.69 | -18.66 | -18.69 | -9.09 | -1.72 | -1.03 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.85x | 0.83x | 0.93x | 0.71x | 0.92x | 4.04x | 1.42x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYCN Key Ratios
Cyclerion Therapeutics, Inc. (CYCN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -281.86% | -98.97% | -95.87% | -150.19% | -48.42% | -30.36% | -39.34% |
| Return on Invested Capital (ROIC) | - | - | -294.86% | -97.61% | -183.5% | - | -2468.42% | -58.3% | -65.07% |
| Gross Margin | - | - | -2010.94% | -2357.06% | 100% | -1778.45% | - | 100% | 100% |
| Net Margin | - | - | -2729.27% | -3388.59% | -1555.63% | -14841.08% | - | -152.85% | -170.11% |
| Debt / Equity | - | - | 0.76x | 0.77x | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -3394.63x | - | - | - | - |
| FCF Conversion | 0.86x | 0.85x | 0.83x | 0.93x | 0.71x | 0.92x | 4.04x | 1.42x | 0.94x |
| Revenue Growth | - | - | - | -49.06% | 44.6% | -91.05% | -100% | - | 3.7% |
CYCN SEC Filings & Documents
Cyclerion Therapeutics, Inc. (CYCN) SEC filings — annual & quarterly reports (10-K, 10-Q)
CYCN Frequently Asked Questions
Cyclerion Therapeutics, Inc. (CYCN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cyclerion Therapeutics, Inc. (CYCN) reported $2.1M in revenue for fiscal year 2025.
Cyclerion Therapeutics, Inc. (CYCN) grew revenue by 3.7% over the past year. Growth has been modest.
Cyclerion Therapeutics, Inc. (CYCN) reported a net loss of $3.5M for fiscal year 2025.
Dividend & Returns
Cyclerion Therapeutics, Inc. (CYCN) has a return on equity (ROE) of -39.3%. Negative ROE indicates the company is unprofitable.
Cyclerion Therapeutics, Inc. (CYCN) had negative free cash flow of $3.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More CYCN
Cyclerion Therapeutics, Inc. (CYCN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates